Search research articles
Contact Us
Filters
Showing results (11-20 of 381) with videos related to
Page
of 39
Sort By:
Leukemia
|
May 4, 2018
Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
Herve Avet-Loiseau, Thierry Facon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2011
Genomics in multiple myeloma
Nikhil C Munshi, Hervé Avet-Loiseau
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2017
Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy
Jean-Luc Harousseau, Herve Avet-Loiseau
Blood
|
March 1, 2024
Smoldering multiple myeloma: taking the narrow over the wide path?
Herve Avet-Loiseau, Nizar J Bahlis
Blood
|
January 29, 2015
Genetics of multiple myeloma: another heterogeneity level?
Jill Corre, Nikhil Munshi, Hervé Avet-Loiseau
Medical Oncology (Northwood, London, England)
|
February 21, 2013
8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma
A Gmidène, A Saad, H Avet-Loiseau
Medecine Sciences : M/S
|
December 5, 2017
[Circulating exosomal microRNA as biomarkers in mutiple myeloma]
Salomon Manier, Xavier Leleu, Hervé Avet-Loiseau
Presse Medicale (Paris, France : 1983)
|
May 19, 2007
[Malignant transformation of monoclonal gammopathy of undetermined significance]
Olivier Decaux, Hervé Avet-Loiseau, Bernard Grosbois
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
September 21, 2018
Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside
Aurore Perrot, Jill Corre, Hervé Avet-Loiseau
JAMA Oncology
|
July 19, 2019
Monoclonal Gammopathy May Be of Unpredictable Significance
Nikhil C Munshi, Sundar Jagannath, Herve Avet-Loiseau
Page
of 39
Search research articles
Search
Showing results (11-20 of 381) with videos related to
Sort By:
Page
of 39
Leukemia
|
May 4, 2018
Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
Herve Avet-Loiseau, Thierry Facon
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2011
Genomics in multiple myeloma
Nikhil C Munshi, Hervé Avet-Loiseau
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2017
Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy
Jean-Luc Harousseau, Herve Avet-Loiseau
Blood
|
March 1, 2024
Smoldering multiple myeloma: taking the narrow over the wide path?
Herve Avet-Loiseau, Nizar J Bahlis
Blood
|
January 29, 2015
Genetics of multiple myeloma: another heterogeneity level?
Jill Corre, Nikhil Munshi, Hervé Avet-Loiseau
Medical Oncology (Northwood, London, England)
|
February 21, 2013
8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma
A Gmidène, A Saad, H Avet-Loiseau
Medecine Sciences : M/S
|
December 5, 2017
[Circulating exosomal microRNA as biomarkers in mutiple myeloma]
Salomon Manier, Xavier Leleu, Hervé Avet-Loiseau
Presse Medicale (Paris, France : 1983)
|
May 19, 2007
[Malignant transformation of monoclonal gammopathy of undetermined significance]
Olivier Decaux, Hervé Avet-Loiseau, Bernard Grosbois
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
September 21, 2018
Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside
Aurore Perrot, Jill Corre, Hervé Avet-Loiseau
JAMA Oncology
|
July 19, 2019
Monoclonal Gammopathy May Be of Unpredictable Significance
Nikhil C Munshi, Sundar Jagannath, Herve Avet-Loiseau
Page
of 39